# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated N...
Bristol Myers Squibb (NYSE:BMY) today announced results from three updated analyses from the CheckMate -77T, CheckMate -816, an...
First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improveme...
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, ma...
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest w...